Immunome shares seesaw after reporting antibody ‘cocktail’ passes test against live omicron virus

During the past two years, Immunonome has received more than $17.5 million from the U.S. Department of Defense’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense to support the company’s development of the new drug candidate.

Leave a Reply